Phase 3 Recruiting NIH
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04269902
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Anchorage Radiation Therapy Center — Anchorage, Alaska
+ 621 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monocl…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT03150693
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Anchorage Radiation Therapy Center — Anchorage, Alaska
+ 452 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07321652
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Kaiser Permanente-Anaheim — Anaheim, California
- Kaiser Permanente-Baldwin Park — Baldwin Park, California
+ 221 more sites in the U.S.
Phase 3 Recruiting Network
This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs …
Sponsor: Children's Oncology Group
NCT ID: NCT04293562
Locations: - Children's Hospital of Alabama — Birmingham, Alabama
- USA Health Strada Patient Care Center — Mobile, Alabama
- Banner Children's at Desert — Mesa, Arizona
+ 183 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with newly diagnosed Acute Myeloid Leukemia (AML) with a mutatio…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06852222
Locations: - University of Alabama at Birmingham — Birmingham, Alabama
- Cancer Treatment Center of America Phoenix — Goodyear, Arizona
- The University of Arizona Cancer Center — Tucson, Arizona
+ 56 more sites in the U.S.
Phase 3 Recruiting Industry
Study comparing efficacy and safety of olverembatinib (investigational arm) vs. bosutinib (control arm) in patients with CML-CP (Part A). Study will also evaluate efficacy and safety of olverembatinib (single-arm) in CML-CP patients with T…
Sponsor: Ascentage Pharma Group Inc.
NCT ID: NCT06423911
Locations: - Ascentage Investigative Site #1044 — Birmingham, Alabama
- Ascentage Investigative Site #1112 — Anchorage, Alaska
- Ascentage Investigative Site #1111 — Goodyear, Arizona
+ 47 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of tacabrutideg alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had…
Sponsor: BeOne Medicines
NCT ID: NCT06973187
Locations: - University of Alabama At Birmingham Hospital — Birmingham, Alabama
- Mayo Clinic Phoenix — Phoenix, Arizona
- Kaiser Permanente Southern California — Irvine, California
+ 46 more sites in the U.S.
Phase 3 Recruiting Industry
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136559
Locations: - USA Mitchell Cancer Institute ( Site 0014) — Mobile, Alabama
- Banner MD Anderson Cancer Center ( Site 0059) — Gilbert, Arizona
- Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0051) — Phoenix, Arizona
+ 43 more sites in the U.S.
Phase 3 Recruiting Network
This phase III trial compares the effect of xylitol dental wipes to dental wipes without xylitol for the reduction of bloodstream infection in children with acute myeloid leukemia (AML). Xylitol is a naturally occurring sugar compound foun…
Sponsor: Children's Oncology Group
NCT ID: NCT07022678
Locations: - Children's Hospital of Alabama — Birmingham, Alabama
- Arkansas Children's Hospital — Little Rock, Arkansas
- Valley Children's Hospital — Madera, California
+ 36 more sites in the U.S.
Phase 3 Recruiting Industry
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety of venetoclax in combination with obinutuzumab or acalabrutinib in the treatment of CLL. Adverse even…
Sponsor: AbbVie
NCT ID: NCT06428019
Locations: - Arizona Oncology - Tucson - Rudasill /ID# 267552 — Tucson, Arizona
- Southern VA Health Care System /ID# 266254 — Tucson, Arizona
- UCSF FRESNO/Community Cancer Institute /ID# 270874 — Clovis, California
+ 29 more sites in the U.S.
Phase 3 Recruiting Industry
This is a multi-center, randomized, double-blinded, placebo controlled trial.
Sponsor: Priothera SAS
NCT ID: NCT05429632
Locations: - University of Alabama Hospital (UAB Hospital) — Birmingham, Alabama
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- City of Hope Comprehensive Cancer Center - Duarte — Duarte, California
+ 18 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part …
Sponsor: Loxo Oncology, Inc.
NCT ID: NCT05254743
Locations: - Pacific Cancer Medical Center, Inc — Anaheim, California
- TOI Clinical Research — Cerritos, California
- Stanford School of Medicine-Cancer Clinical Trials Office — Palo Alto, California
+ 16 more sites in the U.S.